Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733775 | 0.77 | HIF1A (0.57) | ACKR3KDM4ECYP2D6CYP2C9HIF1A | |
| SCHEMBL6733742 | 0.74 | ALDH1A1 (0.56) | KDM4ECYP2D6CYP2C9HIF1ACDK5 | |
| SCHEMBL6737254 | 0.74 | CYP2D6 (0.44) | ACKR3KDM4ECYP2D6CYP2C9HIF1A | |
| SCHEMBL6736756 | 0.74 | CDK5 (0.48) | ACKR3KDM4ECYP2D6CYP2C9HIF1A | |
| SCHEMBL28835431 | 0.73 | HSD17B10 (0.36) | KDM4ECYP2C9MEN1ALDH1A1KMT2A | |
| SCHEMBL6735403 | 0.71 | ACP1 (0.50) | KDM4ECDK5CDK5R1MEN1ALDH1A1 | |
| SCHEMBL12563565 | 0.70 | CYP2D6 (0.69) | KDM4ECYP2D6CYP2C9HIF1AMEN1 | |
| SCHEMBL6730138 | 0.69 | SMN1; SMN2 (0.51) | ACKR3KDM4ECYP2D6CYP2C9HIF1A | |
| SCHEMBL6734315 | 0.69 | HRH3 (0.54) | KDM4ECYP2D6CYP2C9HIF1ACDK5 | |
| SCHEMBL1373046 | 0.68 | CYP2D6 (0.67) | KDM4ECYP2D6CYP2C9HIF1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087063-A1 | IMIDAZOLIDINE COMPOUNDS AS CHEMOKINE RECEPTOR MODULATORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | ACKR3 825/4885KDM4E 4423/4885CYP2D6 685/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | ACKR3 825/4885KDM4E 4423/4885CYP2D6 685/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | ACKR3 825/4885KDM4E 4423/4885CYP2D6 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.